Contact Congress about S. 3014: Ensuring Timely Access to Generics Act of 2025
This bill would tighten the rules for petitions that can slow FDA approval of cheaper medicines. Anyone who wants to sue over some drug approvals would first have to raise the issue with FDA, usually within 180 days.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Ensuring Timely Access to Generics Act of 2025 is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Latest action on S. 3014: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who this affects: This bill mainly affects drug companies, biosimilar makers, FDA, and people who may challenge drug approvals in court. It could also matter for patients, pharmacies, health plans, and employers if it changes how quickly lower-cost medicines reach the market.
Why this matters: Cheaper medicines can be delayed when petitions are used mainly to slow competitors instead of raising real safety or legal concerns. This bill tries to push those concerns to FDA earlier and make delay tactics easier to spot. It could speed some approvals, but it could also limit court options for people who miss the filing window or learn new facts late.
Key provisions in S. 3014
- FDA would have to look at listed warning signs when judging if a petition was mainly meant to delay approval. This applies to follow-on drugs, generic drugs, and biosimilars.
- FDA could look at when the filer learned the facts and how close the petition came to an expected approval date. It could also look at repeated petitions, weak evidence, repeated issues, and requests for tougher rules than FDA used for the original drug or the filer’s own drug.
- FDA could also look at other facts that matter. It could issue or update guidance, which is FDA advice on how it plans to apply those factors.
- Anyone who wants to use a lawsuit to stop, slow, undo, or block certain drug or biosimilar applications would have to go to FDA first. They would do that by filing a citizen petition.
- The petition and any updates would have to include the full case. That means all facts and arguments the filer plans to use in the related lawsuit.
How Modern Action helps you take action on S. 3014
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Questions people ask about S. 3014
- What is S. 3014?
- This bill would tighten the rules for petitions that can slow FDA approval of cheaper medicines. Anyone who wants to sue over some drug approvals would first have to raise the issue with FDA, usually within 180 days.
- How do I support or oppose S. 3014?
- Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
- Who should I contact about S. 3014?
- Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
- Can Modern Action explain S. 3014 before I act?
- Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.
